戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 er neurologic deterioration in patients with leptomeningeal metastasis.
2 arding methods of diagnosis and treatment of leptomeningeal metastasis.
3 F-liberating proteases that could facilitate leptomeningeal metastasis.
4 er neurologic deterioration in patients with leptomeningeal metastasis.
5 e systemic therapy may benefit patients with leptomeningeal metastasis and obviate the need for intra
6 e systemic therapy may benefit patients with leptomeningeal metastasis and obviate the need for intra
7  include central nervous system prophylaxis, leptomeningeal metastasis, and common hematologic compli
8 ts increasingly utilized in the treatment of leptomeningeal metastasis are targeted mAbs such as ritu
9 tilized intra-CSF agents in the treatment of leptomeningeal metastasis are targeted monoclonal antibo
10 lide cerebrospinal fluid (CSF) flow study if leptomeningeal metastasis-directed therapy is being cons
11 ed therapeutically beneficial in suppressing leptomeningeal metastasis in these preclinical models.
12                                Evaluation of leptomeningeal metastasis includes contrast-enhanced bra
13 single most important aspect to diagnosis of leptomeningeal metastasis is considering and pursuing th
14                        Although treatment of leptomeningeal metastasis is palliative with median pati
15                        Although treatment of leptomeningeal metastasis is palliative with median pati
16                                              Leptomeningeal metastasis occurs in approximately 3-5% o
17                                              Leptomeningeal metastasis occurs in approximately 5% of
18                                 Treatment of leptomeningeal metastasis often requires involved-field
19                     We molecularly dissected leptomeningeal metastasis, or spread of cancer to the ce
20                                   Staging of leptomeningeal metastasis should include contrast-enhanc
21 survival of 2-3 months (15% of patients with leptomeningeal metastasis survive 1 year), treatment may
22 iew of methods of diagnosis and treatment of leptomeningeal metastasis was performed.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。